Effect of Meloxicam on Gingival Crevicular Fluid IL-1beta and IL1 Receptor Antagonist Levels in Subjects With Chronic Periodontitis, and Its Effects on Clinical Parameters

Basit Öğe Kaydı
dc.contributor.authorToker, Hülya
dc.contributor.authorMarakoğlu, İsmail
dc.contributor.authorPoyraz, Ömer
dc.date.accessioned2020-03-26T17:03:24Z
dc.date.available2020-03-26T17:03:24Z
dc.date.issued2006
dc.departmentSelçuk Üniversitesien_US
dc.descriptionIADR 2004 Meeting -- AUG 25-28, 2004 -- Istanbul, TURKEYen_US
dc.description.abstractThe aim of the present study was to determine the effects of meloxicam after initial periodontal treatment on interleukin-1beta (IL-1 beta) and IL-1 receptor antagonist (IL-1ra) in gingival crevicular fluid (GCF) and clinical parameters in the chronic periodontitis patients. Data were obtained from 30 patients with chronic periodontitis. Fifteen chronic periodontitis patients received 7.5 mg meloxicam, and 15 patients received placebo tablets in a 1x1 regimen for 1 month. All subjects were nonsmokers and had not received any periodontal therapy. The plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment level (CAL) were recorded. The GCF was collected using a paper strip: eluted and enzyme-linked immunoabsorbent assays (ELISAs) were performed to determine the cytokine levels. The clinical data and GCF samples were obtained after periodontal therapy and 1 month after periodontal therapy. The PI, GI, PD, and GCF IL-1ra decreased significantly (p < 0.05) in meloxicam group at first month when comparing the initial levels. While decrease of the PI was statistically significant in control group (p < 0.05), statistically significant changes were not determined in the other clinical parameters and GCF cytokine levels (p > 0.05). There were no significant differences between two groups in any of the investigated parameters. Our observations did not reveal any influence of meloxicam on levels of IL-1 beta and IL-1ra in chronic periodontitis. Additional clinical studies are advisable to determine whether COX-2 selective drugs alter periodontal disease outcome with greater safety.en_US
dc.description.sponsorshipIadren_US
dc.identifier.citationPoyraz, Ö., Marakoğlu, İ., Toker, H., (2006). Effect of Meloxicam on Gingival Crevicular Fluid IL-1beta and IL1 Receptor Antagonist Levels in Subjects With Chronic Periodontitis, and Its Effects on Clinical Parameters. Clinical Oral Investigations, (10), 305-310. Doi: 10.1007/s00784-006-0062-3
dc.identifier.doi10.1007/s00784-006-0062-3en_US
dc.identifier.endpage310en_US
dc.identifier.issn1432-6981en_US
dc.identifier.issn1436-3771en_US
dc.identifier.pmid16896836en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage305en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00784-006-0062-3
dc.identifier.urihttps://hdl.handle.net/20.500.12395/20447
dc.identifier.volume10en_US
dc.identifier.wosWOS:000242420800006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorMarakoğlu, İsmail
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofClinical Oral Investigationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectchronic periodontitisen_US
dc.subjectmeloxicamen_US
dc.subjectIL-1 betaen_US
dc.subjectIL-1raen_US
dc.titleEffect of Meloxicam on Gingival Crevicular Fluid IL-1beta and IL1 Receptor Antagonist Levels in Subjects With Chronic Periodontitis, and Its Effects on Clinical Parametersen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
20447.pdf
Boyut:
207.14 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Peridontoloji/Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu